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ABSTRACT
Telomeric dysfunction is linked to colorectal cancer (CRC) initiation. However, 
the relationship of normal tissue and tumor telomere lengths with CRC progression, 
molecular features and prognosis is unclear. Here, we measured relative telomere 
length (RTL) by real-time quantitative PCR in 90 adenomas (aRTL), 419 stage I-IV 
CRCs (cRTL) and adjacent normal mucosa (nRTL). Age-adjusted RTL was analyzed 
against germline variants in telomere biology genes, chromosome instability (CIN), 
microsatellite instability (MSI), CpG island methylator phenotype (CIMP), TP53, 
KRAS, BRAF mutations and clinical outcomes. In 509 adenoma or CRC patients, 
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nRTL decreased with advancing age. Female gender, proximal location and the TERT 
rs2736100 G allele were independently associated with longer age-adjusted nRTL. 
Adenomas and carcinomas exhibited telomere shortening in 79% and 67% and 
lengthening in 7% and 15% of cases. Age-adjusted nRTL and cRTL were independently 
associated with tumor stage, decreasing from adenoma to stage III and leveling 
out or increasing from stage III to IV, respectively. Cancer MSI, CIMP, TP53, KRAS 
and BRAF status were not related to nRTL or cRTL. Near-tetraploid CRCs exhibited 
significantly longer cRTLs than CIN- and aneuploidy CRCs, while cRTL was significantly 
shorter in CRCs with larger numbers of chromosome breaks. Age-adjusted nRTL, 
cRTL or cRTL:nRTL ratios were not associated with disease-free or overall survival 
in stage II/III CRC. Taken together, our data show that both normal mucosa and 
tumor RTL are independently associated with CRC progression, and highlight divergent 
associations of CRC telomere length with tumor CIN profiles.
INTRODUCTION
Telomeres are specialized structures composed of 
(TTAGGG)n tandem nucleotide repeats and protein that 
cap at the ends of linear eukaryotic chromosomes. They 
have an essential role in maintaining genomic integrity 
by protecting chromosomes from end-to-end fusion 
and exonucleolytic degradation [1]. In normal human 
somatic cells, telomeres have an average length of 5 to 15 
kilobases and shorten by ~30 to 200 base pairs every cell 
division due to the incomplete semi-conservative nature 
of DNA replication, the so-called end-replication problem 
[2]. In addition to the mitotic replication rate, endogenous 
and exogenous factors such as gender, oxidative stress, 
smoking and obesity contribute to the rate of telomere 
attrition [3]. With continuous shortening, telomeres 
eventually reach a critical length that triggers the activation 
of the p53 and/or RB tumor suppressor pathways and 
provides the signal for replicative senescence and 
apoptosis [4]. Cells that aberrantly bypass senescence and 
continue to divide suffer telomere attrition culminating 
in chromosome breakage-fusion-bridge (BFB) cycles 
and genome instability [5]. In immortal cells, telomere 
shortening is ultimately arrested either by the inappropriate 
activation of telomerase, a ribonucleoprotein complex 
consisting of telomerase reverse transcriptase (TERT) and 
an internal RNA component (TERC), or less commonly 
by the recombination-mediated alternative lengthening 
of telomeres (ALT) pathway [6, 7]. Telomere dysfunction 
is considered a major contributor to cancer development. 
Telomeres in human cancers are often shorter or elongated 
as compared to the surrounding normal tissue, telomere 
attrition and BFB results in numerical and structural 
chromosomal changes, and tumors frequently exhibit 
aberrant telomerase activation or ALT [5-7]. Accordingly, 
mouse models of excessive telomere shortening display 
increased tumor risk [8].
In human colorectal cancer (CRC), 39% to 97% 
(mean = 72%) of carcinomas have been reported to exhibit 
shorter telomeres as compared to adjacent normal mucosa, 
with the large range of estimates at least partly reflecting 
differences in analytical methods and classification cut-
offs used [9-15]. Telomere shortening is considered an 
early event in colorectal tumorigenesis, with decreased 
telomere lengths reported in up to 64% of adenomas [10, 
16, 17].
The role of telomere dysfunction in CRC 
progression remains controversial. Some studies report 
that telomeres are shorter in carcinomas as compared 
to adenomas [9, 10, 18], while others have observed no 
difference or opposite results [19, 20]. Among carcinomas, 
several investigators have identified that telomeres are 
longer in more advanced cases, and have suggested 
this may be explained by progressive re-activation 
of telomerase or ALT [9, 11, 12, 20], Others have not 
confirmed a correlation between cancer telomere length 
and disease stage [13, 14]. Inconclusive findings exist for 
associations between cancer telomere length and tumor 
location [9, 11-14] or differentiation [12, 14].
Limited data are available on the relationship 
between cancer telomere length and clinical outcomes 
for early-stage CRC. Three studies have identified 
longer cancer telomere length or higher cancer to non-
cancer tissue telomere length ratios as predictors of poor 
prognosis [11, 12, 14], although results for disease-free 
and overall survival were not always consistent. Another 
has reported opposite results, with shorter telomeres 
associated with worse survival [9].
Few studies have examined the relationship between 
telomere length and chromosome instability (CIN) profiles 
in CRC, or investigated other global molecular phenotypes 
such as microsatellite instability (MSI+) – where there is 
a propensity to insertion and deletion mutations at simple 
tandem repeats due to defective DNA mismatch repair 
(MMR) – or CpG island methylator phenotype (CIMP+). 
Consistent with a role of telomere dysfunction in driving 
CIN+, telomere shortening in colorectal polyps from 
patients with familial adenomatous polyposis has recently 
been correlated with large-scale genomic rearrangements 
[17]. In a study of patients with MSI- rectal cancers shorter 
tumor telomeres were similarly associated with CIN+ and 
activation of telomerase [15]. In contrast, MSI-/CIN- 
rectal cancers were found to have longer telomeres than 
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MSI-/CIN+ rectal cancers and to exhibit ALT rather than 
telomerase activation [15]. Two studies have reported that 
MSI+ cancers have shorter telomeres than MSI- cancers 
[13, 21]. Limited data are available on the association 
between telomere length and somatic mutation profiles 
such as changes in TP53, KRAS and BRAF [22, 23].
Twin studies and population-based surveys have 
established that normal telomere length is largely genetically 
determined [24]. Accordingly, telomere length has been 
linked to common variants in multiple genes related to 
telomere biology such as TERC, TERT, MEN1, OBFC1 
RECQL5 and RTEL1 [25-27]. Telomere length of peripheral 
blood leukocytes (PBL) and variants in TERT and TERC 
have been associated with CRC susceptibility, with evidence 
that both shorter and longer telomere lengths may play a 
role [28-30]. One study has identified PBL telomere length 
as an independent prognostic marker for CRC [31].
Here, we analyzed 509 patients with colorectal 
adenoma or carcinoma to define the major clinical and 
germline modifiers associated with RTL in normal 
colorectal mucosa, and to clarify the respective 
contributions of normal and tumor RTL to CRC initiation 
and progression. We further investigated the relationships 
of normal and tumor RTL with somatic mutation, CIMP, 
MSI and CIN profiles, and evaluated their respective 
prognostic value in stage II/III CRC.
RESULTS
RTL of cancer and normal mucosa in patients 
with CRC
Four hundred and nineteen patients with stage 
I-IV CRCs were screened for RTL of cancer (cRTL) and 
histologically normal adjacent mucosa (nRTL), MSI, and 
mutations in KRAS, BRAF, PIK3CA and TP53. CIMP 
status was analyzed in 382 cancers. SNP microarray data, 
available on 349 matched tumor and normal samples 
[30], were analyzed for tumor CIN profiles and germline 
variants in 15 genes previously associated with telomere 
length in the population-based studies (ACYP2, BCL2L1, 
CTC1, CXCR4, MEN1, MRE11A, NAF1, OBFC1, 
RECQL5, RTEL1, TERC, TERT, TNKS, ZNF208 and 
ZNF676) (Supplementary Table 1).
Consistent with other studies, mutations in KRAS 
were detected in 34.4% (144/419), BRAF in 11.2% 
(47/419), PIK3CA in 14.1% (59/419) and TP53 in 55.0% 
(229/416) of cases. MSI+ and CIN+ was identified 
in 17.2% (72/419) and 73.6% (257/349) of cancers, 
respectively. Among CIN+ cancers, 16.0% (41/257) were 
near-tetraploid and 84.0% (216/257) aneuploidy, with 
the number of chromosome breaks ranging from 0 to 
110 (mean=18) (Figure 3A). 19.6% (75/382) of cancers 
were CIMP+. MSI+ and CIN+ showed a strong inverse 
association (OR=0.05), and KRAS and BRAF mutations 
were nearly mutually exclusive (OR=0.03).
RTL measured using the multiplex quantitative 
polymerase chain reaction (qPCR) method developed 
by Cawthon [32] has previously been shown to highly 
correlate with absolute telomere length measurements 
in tumor and normal samples as determined by Southern 
blotting [13]. Accordingly, we found that copy number 
of the human beta globin gene, used as internal assay 
control, was highly correlated with total chromosome 
number in our tumors as determined from SNP array data 
(r=0.86, P<0.001; Supplementary Figure 1). The inter-
assay coefficient of variability (CV) for qPCR repeat 
assays was 7.5% for normal and 8.4% for tumor samples 
(Supplementary Figure 2). Matched tumor and normal 
samples were analyzed in the same qPCR plate together 
with references cell line samples with established short 
telomere length of 3.76 kb (TF-1: human hematopoietic 
progenitor cell line [33]) and long telomere lengths 
of 9.92 kb (TF-1/TI2G: TF-1 cell line with retroviral 
overexpression of hTERT [33]) which were readily 
distinguished (TF1: RTL mean=0.73, SD=0.13; TF-1/
TI2G: RTL mean=3.06, SD=0.37; Supplementary Figure 
3). As anticipated, nRTL decreased significantly with older 
age (P<0.001), and normal and tumor RTL measurements 
were age-adjusted accordingly using residuals as described 
by Robles-Espinoza et al. (Supplementary Figure 4) [34].
Age-adjusted telomere length in cancers was 
significantly shorter as compared to adjacent mucosa, with 
a cRTL mean of -0.06 (SD=0.51) and an nRTL mean of 
-0.47 (SD=0.69), respectively (P<0.001). Considering 2x 
the mean standard deviation of nRTL repeat measurements 
(2xNSD) as cut-off, 67.3% (282/419) of cancers exhibited 
telomere shortening and 14.6% (61/419) telomere 
lengthening, consistent with previous reports evaluating 
absolute telomere length (Figure 1) [9-15].
RTL of normal colorectal mucosa is related to 
patient baseline characteristics and germline 
variants in telomere biology genes
We tested whether age-adjusted nRTL in 
histologically normal colorectal mucosa from CRC 
patients was related to previously implicated baseline 
clinical and germline modifiers by first considering 28 
common variants linked to telomere length in the general 
population (Supplementary Table 1). In our cohort, the 
TERT2 intron 2 variant rs2736100 was significantly 
associated with nRTL (FDR-adjusted P<0.037), with the 
G allele linked to longer telomere length consistent with 
previous reports [30]. Considering patient gender, site 
of tissue sampling and rs2736100 status in multivariate 
analysis, female gender, proximal location and rs2736100 
G allele were independently associated with longer age-
adjusted nRTL (P<0.049 for all comparisons, Table 1A). 
For the subset of individuals for whom BMI and smoking 
history details were available (n=229), these variables 
were not correlated with nRTL (multivariate P>0.417 for 
both comparisons, Table 1B).
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RTL of normal colorectal mucosa is associated 
with CRC stage at presentation
We next investigated the relationship between 
age-adjusted nRTL and the pathological and molecular 
features of the associated cancer (Table 2). In multivariate 
analysis including gender, location and rs2736100 
genotype, nRTL was progressively shorter with increasing 
tumor stage at presentation for stages I to III, (nRTL 
mean±SD: stage I 0.07±0.51, stage II -0.02±0.55, stage 
III -0.13±0.47; P=0.005, Mann-Kendall trend test), but 
was similar between stages III and IV (nRTL mean±SD: 
stage III -0.13±0.47, stage IV -0.15±0.42; P=0.387) 
(Figure 2A). No relationship was detected between nRTL 
and tumor differentiation (multivariate P=0.760). CRC 
molecular features including MSI, CIN profile, number of 
chromosome breaks, CIMP and mutation in BRAF, KRAS 
and TP53 showed no associations with nRTL (multivariate 
P>0.057 for all comparisons).
RTL of CRC varies with disease stage and is 
related to tumor CIN profile
Clinicopathological and molecular correlates of 
cancer telomere length were evaluated overall (age-
adjusted cRTL) and as a change from normal telomere 
length (age-adjusted cRTL:nRTL ratio) in multivariate 
analysis (Table 2). As observed for nRTL, shorter cRTL 
was related to advanced tumor stage decreasing from 
stage I to III (cRTL mean±SD: stage I -0.21±0.80, stage 
II -0.51±0.66, stage III -0.56±0.65; P=0.001, Mann-
Kendall trend test). cRTL showed evidence of a modest 
increase from stage III to IV (cRTL mean±SD: stage III 
-0.56±0.65, stage IV -0.54±0.70; P=0.027) (Figure 2B). 
A similar but weaker trend was observed when examining 
cRTL:nRTL ratios (Table 2). Consistent with the observed 
increase in cRTL between stage IV and earlier tumor 
stages, liver metastases available for 11 cases tended 
to show cRTL lengthening as compared to the matched 
primary cancers (cRTL mean±SD: primary -0.79±0.26, 
metastasis -0.41±0.53; P=0.024) (Figure 2C). Notably, 
nRTL and cRTL were independent predictors of tumor 
stage (nRTL P=0.013, cRTL P=0.013). No association 
was detected between cRTL and tumor differentiation 
(multivariate P=0.225) or location (multivariate P>0.454). 
BMI and smoking history were not associated with cRTL 
(multivariate P=0.787 and P=0.521, respectively).
CRC molecular features including MSI, CIMP 
and mutations in BRAF, KRAS and TP53 were not 
associated with age-adjusted cRTL or cRTL:nRTL ratios 
(multivariate P>0.115 for all comparisons) (Table 2). 
Shorter telomeres in MSI+ cancers have previously been 
reported in tumors with TP53 wild-type status [13], but 
this was not confirmed in a corresponding subset analysis 
of our cohort (multivariate cRTL P=0.524, cRTL:nRTL 
ratio P=0.157). However, cRTL showed a divergent 
association in relation to tumor CIN profiles: cRTL was 
significantly longer in near-tetraploid tumors as compared 
to CIN- and aneuploidy tumors (multivariate P<0.046 
for both comparisons), whereas cRTL was significantly 
shorter in tumors with larger numbers of chromosome 
breaks (multivariate P=0.009) (Table 2, Figure 3). These 
associations remained significant when restricting the 
analysis to MSI- tumors (multivariate P≤0.028). A 
similar but weaker trend was observed when examining 
cRTL:nRTL ratios (Table 2).
Adenoma patients tend to have longer normal 
mucosa RTL and more prevalent tumor telomere 
shortening than carcinoma patients
To examine the role of normal and tumor telomere 
length in early carcinogenesis, 90 patients with large 
(>1cm) tubular or tubulovillous adenomas were screened 
for RTL of neoplastic (age-adjusted aRTL) and adjacent 
normal mucosa (age-adjusted nRTL). As anticipated, 
Figure 1: Differences in age-adjusted RTLs between tumor and normal colorectal mucosa for A. carcinoma and B. 
adenoma patients. Considering 2x the mean standard deviation of nRTL repeat measurements as a cut-off, 67% of carcinomas and 79% 
of adenomas show telomere shortening (green bars), and 15% of carcinomas and 7% of adenomas show telomere lengthening (red bars).
A B
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Table 1: Characteristics of patients with CRC according to age-adjusted RTL of normal mucosa (nRTL) 
A. Clinical Features All
nRTL P P
Mean±SD (Uni.) (Multi.)
Gender n=419
 Male 223 -0.13 ± 0.46
 Female 196 0.02 ± 0.54 0.002* 0.002*
Site n=419
 Right 195 0.00 ± 0.51
 Left 142 -0.11 ± 0.53 0.052 0.049*
 Rectum 82 -0.1 ± 0.44 0.129 0.280
rs2736100 n=389
 TT 111 -0.15 ± 0.43
 TG 201 -0.08 ± 0.53
 GG 77 0.13 ± 0.55 <0.001* <0.001*
B. Lifestyle factors
BMI n=229
 Mean± SD 27.6 ± 5 - 0.522 0.417
 Median 27.7
 Range 15.2 to 43.1
Smoking n=324
 No 169 -0.08 ± 0.51
 Yes 155 -0.12 ± 0.53 0.446 0.723
A. Baseline clinical features and rs2736100 genotype, and B. lifestyle factors.
Uni. = univariate; Multi. = multivariate; *P<0.05.
Figure 2: Age-adjusted RTL for A. normal mucosa by stage of disease, B. tumor by stage of disease, and C. matched 
primary cancer and metastasis pairs. Pairwise differences with P<0.05 are indicated.
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Table 2: Clinicopathological and molecular characteristics of patients with CRC according to age-adjusted RTL of 
normal mucosa (nRTL), cancer (cRTL) and cRTL/nRTL ratio 
Clinical Features All
nRTL P P cRTL P P cRTL/nRTL P P
Mean±SD (Uni.) (Multi.) Mean±SD (Uni.) (Multi.) Mean±SD (Uni.) (Multi.)
Stage n=419
 I (Ref.) 71 0.07 ± 0.51 -0.21 ± 0.80 -0.45 ± 0.85
 II 155 -0.02 ± 0.55 0.213 0.090 -0.51 ± 0.66 0.003* 0.250 -0.76 ± 1.04 0.027* 0.355
 III 151 -0.13 ± 0.47 0.007* 0.005* -0.56 ± 0.65 <0.001 0.007* -0.72 ± 0.96 0.059 0.165
 IV 42 -0.15 ± 0.42 0.03* 0.002 -0.54 ± 0.70 0.015* 0.600 -0.66 ± 0.92 0.271 0.596
 II (Ref.) 155 -0.02 ± 0.55 -0.51 ± 0.66 -0.76 ± 1.04
 III 151 -0.13 ± 0.47 0.069 0.074 -0.56 ± 0.65 0.486 0.015* -0.72 ± 0.96 0.687 0.455
 IV 42 -0.15 ± 0.42 0.158 0.036* -0.54 ± 0.7 0.806 0.602 -0.66 ± 0.92 0.548 0.108
 III (Ref.) 151 -0.13 ± 0.47 -0.56 ± 0.65 -0.72 ± 0.96
 IV 42 -0.15 ± 0.42 0.827 0.387 -0.54 ± 0.70 0.832 0.027* -0.66 ± 0.92 0.738 0.033*
Differentiation n=407
 Well/Moderate 321 -0.05 ± 0.52 -0.48 ± 0.70 -0.69 ± 0.98
 Poor 86 -0.13 ± 0.44 0.182 0.760 -0.48 ± 0.67 0.977 0.225 -0.62 ± 0.94 0.560 0.633
Molecular Features
MSI status n=419
 Stable 347 -0.06 ± 0.5 -0.49 ± 0.68 -0.69 ± 0.97
 Unstable 72 -0.04 ± 0.54 0.740 0.106 -0.44 ± 0.74 0.557 0.703 -0.64 ± 0.98 0.674 0.141
Ploidy status n=403
 CIN- (Ref.) 92 -0.08 ± 0.55 -0.62 ± 0.60 -0.84 ± 1.03
 Aneuploid 216 -0.06 ± 0.48 0.726 0.986 -0.56 ± 0.64 0.396 0.207 -0.81 ± 0.98 0.801 0.211
 Near-tetraploid 41 0.02 ± 0.49 0.292 0.898 -0.39 ± 0.61 0.042* 0.015* -0.57 ± 0.82 0.139 0.025*
 Aneuploid (Ref.) 216 -0.06 ± 0.48 -0.56 ± 0.64 -0.81 ± 0.98
 Near-tetraploid 41 0.02 ± 0.49 0.366 0.853 -0.39 ± 0.61 0.105 0.046* -0.57 ± 0.82 0.148 0.079
Chr. breaks n=349
 Mean± SD 17.6 ± 19.1 - 0.170 0.191 - 0.037* 0.009* - 0.128 0.057
 Median 10
 Range 0 to 110
CIMP status n=382
 CIMP- 307 -0.10 ± 0.48 -0.53 ± 0.63 -0.68 ± 0.93
 CIMP+ 75 -0.02 ± 0.56 0.204 0.886 -0.41 ± 0.83 0.169 0.946 -0.66 ± 1.06 0.876 0.835
TP53 n=416
 Wild-type 187 -0.05 ± 0.52 -0.52 ± 0.65 -0.74 ± 0.96
 Mutated 229 -0.06 ± 0.50 0.751 0.993 -0.46 ± 0.73 0.375 0.115 -0.64 ± 0.98 0.294 0.226
BRAF n=419
 Wild-type 372 -0.06 ± 0.50 -0.49 ± 0.67 -0.69 ± 0.95
 Mutated 47 -0.08 ± 0.58 0.813 0.861 -0.40 ± 0.87 0.411 0.667 -0.64 ± 1.15 0.753 0.996
KRAS n=419
 Wild-type 275 -0.03 ± 0.54 -0.42 ± 0.75 -0.64 ± 1.00
 Mutated 144 -0.12 ± 0.45 0.090 0.057 -0.59 ± 0.56 0.015* 0.142 -0.75 ± 0.91 0.276 0.941
P-values are for multivariate analysis additionally adjusted for gender, location and rs2736100 genotype.
Uni. = univariate; Multi. = multivariate; *P<0.05.
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adenoma telomere length was significantly shorter 
than matched normal mucosa telomere length, with an 
aRTL mean of -0.38 (SD=0.57) and nRTL mean of 0.27 
(SD=0.48), respectively (P<0.001). Consistent with our 
observation in CRC patients of shorter normal mucosa 
telomere length in individuals with more advanced tumors, 
nRTL in adenoma patients was significantly longer than 
nRTL in CRC patients adjusting for gender and site 
(multivariate P<0.001, Figure 2A).
78.8% (71/90) of adenomas exhibited telomere 
shortening as compared to matched normal mucosa 
using a 2xNSD cut-off, a higher proportion than among 
carcinoma cases (67.3% (282/419); P=0.032). However 
aRTL was overall longer than cRTL (mean±SD: aRTL 
-0.38±0.57 cRTL -0.47±0.69; P=0.012). In contrast, 
telomere lengthening appeared less prevalent in adenomas 
(6.7%, 6/90) than carcinomas (14.6%, 61/419), although 
this did not reach statistical significance (P=0.057).
No prognostic value of normal or cancer RTL in 
stage II/III CRC
We tested whether normal or cancer RTL was 
associated with prognosis in patients with stage II/III CRC, 
adjusting for gender, age, tumor site, stage, differentiation 
and adjuvant treatment. Outcome information was 
available for 281 patients for OS with a median duration 
of follow-up of 45.2 months, and for 246 patients for DFS 
with a median duration of follow-up of 41.6 months.
DFS and OS were similar irrespective of whether 
age-adjusted nRTL or cRTL were considered (multivariate 
P≥0.411 for all comparisons, Table 3). Likewise, 
age-adjusted cRTL:nRTL ratio was not associated 
with differential outcomes (multivariate P≥0.451). 
As anticipated, tumor stage and differentiation were 
independent prognostic factors for DFS, and patient age, 
gender, tumor stage and differentiation were independent 
prognostic factors for OS (Table 3). Similar results were 
obtained when additionally adjusting for tumor MSI and/
or CIN status (data not shown).
DISCUSSION
This study presents the most comprehensive survey 
to date of age-adjusted normal and tumor RTL in patients 
with colorectal adenoma or carcinoma and its relationship 
to clinicopathological characteristics, germline variants 
in telomere biology genes, tumor molecular features and 
outcome.
Telomere length is a heritable trait [24], and 
population-based studies have implicated germline 
variants in several genes related to telomere biology [25-
27]. Considering 28 germline variants reported to date, we 
validated the role of rs2736100 – localized in TERT intron 
2 – with the G allele associated with longer RTL in normal 
mucosa. Notably, the rs2736100 G allele has been linked 
to a lower risk of developing CRC [30].
Besides genetic factors, gender and other 
endogenous and exogenous variables may influence age-
adjusted normal tissue telomere length including smoking 
and obesity [3]. In our cohort, females tended to have 
longer nRTLs than males consistent with population-
Figure 3: Relationship of age-adjusted RTL with CIN profile in CRC. A. Representative examples of SNP array data for 
CIN-, aneuploid and near-tetraploid CRCs. LRR is the log2(observed intensity/reference intensity), while BAF (B Allele Frequency) is 
the relative contribution of one of the alleles over the total allele signal. B-C. Age-adjusted cancer RTL shown by tumor CIN status or the 
number of chromosome breaks. For chromosomal breaks, the age-adjusted cancer RTL is binned by quintiles.
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Table 3: Multivariate Cox proportional-hazards analysis of A. disease-free survival and B. overall survival for 
patients with resected stage II/III CRC according to age-adjusted RTL of normal mucosa (nRTL), cancer (cRTL) 
and cRTL/nRTL ratio. 
A. Disease-free 
survival
nRTL cRTL cRTL/nRTL
n HR (95% CI) P HR (95% CI) P HR (95% CI) P
Relative telomere length
 T/S ratio 246 0.77 ( 0.42 - 1.42 ) 0.411 0.82 ( 0.47 - 1.45 ) 0.502 0.89 ( 0.66 - 1.2 ) 0.451
Age
 Years 246 0.99 ( 0.96 - 1.02 ) 0.374 0.99 ( 0.96 - 1.02 ) 0.483 0.99 ( 0.96 - 1.02 ) 0.469
Gender
 Male 124 1 (Reference) 1 (Reference) 1 (Reference)
 Female 122 0.61 ( 0.35 - 1.07 ) 0.087 0.62 ( 0.35 - 1.1 ) 0.102 0.61 ( 0.35 - 1.08 ) 0.089
Tumor site
 Proximal 
colon 116 1 (Reference) 1 (Reference) 1 (Reference)
 Distal colon 94 0.8 ( 0.42 - 1.51 ) 0.486 0.83 ( 0.44 - 1.57 ) 0.564 0.84 ( 0.44 - 1.58 ) 0.585
 Rectum 36 1.05 ( 0.49 - 2.25 ) 0.905 1.05 ( 0.49 - 2.27 ) 0.898 1.05 ( 0.49 - 2.27 ) 0.900
Tumor stage
 II 130 1 (Reference) 1 (Reference) 1 (Reference)
 III 116 3.06 ( 1.47 - 6.37 ) 0.003* 3.11 ( 1.49 - 6.47 ) <0.001* 3.16 ( 1.52 - 6.59 ) 0.002*
Differentiation
 Well/
Moderate 188 1 (Reference) 1 (Reference) 1 (Reference)
 Poor 58 2.57 ( 1.48 - 4.46 ) 0.001* 2.61 ( 1.51 - 4.54 ) <0.001* 2.63 ( 1.51 - 4.57 ) 0.001*
Adjuvant 
chemotherapy
 No 108 1 (Reference) 1 (Reference) 1 (Reference)
 Yes 138 1.51 ( 0.72 - 3.16 ) 0.279 1.48 ( 0.71 - 3.11 ) 0.299 1.47 ( 0.70 - 3.1 ) 0.307
B. Overall survival
Relative telomere length
 T/S ratio 281 0.82 ( 0.45 - 1.48 ) 0.506 1.15 ( 0.77 - 1.74 ) 0.493 0.99 ( 0.75 - 1.32 ) 0.944
Age
 Years 281 1.03 ( 1.00 - 1.06 ) 0.026* 1.03 ( 1.00 - 1.06 ) 0.035* 1.03 ( 1.00 - 1.06 ) 0.028*
Gender
 Male 146 1 (Reference) 1 (Reference) 1 (Reference)
 Female 135 0.57 ( 0.33 - 0.98 ) 0.044* 0.56 ( 0.32 - 0.96 ) 0.035* 0.57 ( 0.33 - 0.98 ) 0.041*
Tumor site
  Proximal 
colon 132 1 (Reference) 1 (Reference) 1 (Reference)
 Distal colon 101 0.54 ( 0.29 - 1.02 ) 0.056 0.56 ( 0.30 - 1.04 ) 0.066 0.56 ( 0.30 - 1.04 ) 0.067
(Continued )
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based studies examining PBLs [3]. Accordingly, estrogen 
receptor-alpha signaling has been shown to positively 
regulate TERT transcription and telomerase activity [35]. 
Proximal location was associated with longer nRTL in 
our cohort, consistent with the higher baseline telomerase 
reported for this site [36]. We did not find evidence for a 
contribution of smoking and BMI, although these details 
were only available for a subset of individuals.
Age-adjusted nRTL was associated with tumor stage 
at presentation with progressively shorter nRTLs from 
adenoma to stage III/IV carcinoma patients. Interestingly, 
telomere length in PBLs has further been reported to be 
shorter in patients with adenomas than in individuals with 
normal colonoscopies [37]. While a relationship between 
normal tissue telomere length and risk of CRC is well 
documented [28-30], our data suggest that shorter normal 
telomere length may additionally provide a background 
for more rapid cancer progression. Telomere shortening 
in normal epithelium has been implicated as a direct 
precursor to the structural and numerical chromosome 
changes characteristic of CRC [22]. In addition, there is 
evidence that as normal cells with shortened telomeres 
enter senescence they exhibit a secretory phenotype that 
can trigger neighboring cells to by-pass the senescence 
signal, setting the stage for CIN and tumor development 
[38, 39].
Telomere shortening is thought to be an early event 
in colorectal tumorigenesis, although frequency estimates 
for adenomas vary widely [10, 16, 17]. Our observations 
indicate telomere shortening in ~79% of adenomatous 
polyps >1cm in size. Some investigators have described 
telomere lengthening in 14-30% of adenomas [17, 21], but 
we found telomere lengthening in only 7% of cases. Some 
of the discrepancies in published results may be due to 
differences in adenoma sizes and/or histologic subtypes 
analyzed, sample preparation or methods and cut-offs to 
classify telomere behavior.
While there is general agreement that telomere 
dysfunction occurs early in colorectal tumor development, 
the relationship between telomere length and tumor 
progression remains controversial. Some studies report 
that telomeres are shorter in carcinomas as compared to 
adenomas [9, 10, 18], while others do not [19, 20]. We 
found a lower prevalence of telomere shortening in CRCs 
as compared to adenomas, but the extent of telomere 
shortening was greater in CRC, in particular at later 
stages. Telomere lengthening appeared more common 
in carcinomas as compared to adenomas, although this 
did not reach statistical significance. Some investigators 
have reported that telomeres are longer in late-stage 
than early-stage carcinomas [11, 12], while others have 
found the opposite or no association [9, 13, 14]. We 
observed that cRTL significantly decreased from stage I 
to stage III carcinoma, and showed a modest increase to 
stage IV carcinoma. This was independent of nRTL, and 
accordingly cRTL:nRTL ratios showed a similar trend. 
The apparent increase telomere shortening with advanced 
cancer stage likely reflects the activation of telomerase 
and/or ALT with tumor progression [9, 13]. Our data did 
not validate previous suggestions that cancer telomere 
length is associated with tumor differentiation [12] and 
tumor location [12, 13].
Telomere dysfunction leads to CIN, but limited 
data exist on the correlation of telomere length with 
CIN status in CRC. Telomere shortening and telomerase 
activation has been linked to CIN+ in MSI- rectal cancers, 
while MSI- CIN- rectal cancers had longer telomeres and 
appeared to exhibit ALT [15]. We identified a divergent 
association of cancer telomere length depending on the 
tumor CIN profile, with near-tetraploid tumors tending to 
A. Disease-free 
survival
nRTL cRTL cRTL/nRTL
n HR (95% CI) P HR (95% CI) P HR (95% CI) P
 Rectum 48 0.86 ( 0.43 - 1.7 ) 0.660 0.88 ( 0.44 - 1.76 ) 0.724 0.87 ( 0.44 - 1.72 ) 0.682
Tumor stage
 II 143 1 (Reference) 1 (Reference) 1 (Reference)
 III 138 2.97 ( 1.60 - 5.52 ) 0.001* 3.01 ( 1.62 - 5.58 ) <0.001* 3 ( 1.61 - 5.58 ) 0.001*
Differentiation
 Well/
Moderate 215 1 (Reference) 1 (Reference) 1 (Reference)
 Poor 66 2.01 ( 1.18 - 3.41 ) 0.010* 2.05 ( 1.21 - 3.48 ) 0.007* 2.06 ( 1.21 - 3.51 ) 0.007*
Adjuvant 
chemotherapy
 No 121 1 (Reference) 1 (Reference) 1 (Reference)
 Yes 160 1.10 ( 0.59 - 2.05 ) 0.767 1.11 ( 0.59 - 2.07 ) 0.750 1.1 ( 0.59 - 2.06 ) 0.761
*P<0.05
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have longer telomeres, while short cancer telomeres were 
associated with higher numbers of chromosome breaks. 
These data are consistent with an increasing body of data 
suggesting the potential development of two distinct CIN 
profiles initiated by endoreduplication caused by telomere 
dysfunction: maintenance of near-tetraploidy related to 
early telomere stabilization or elongation, potentially 
mediated by ALT [40, 41], and development of aneuploidy 
through subsequent BFB cycles eventually rescued by re-
activation of telomerase [5, 42].
Previous data have suggested that MSI+ cancers 
have shorter telomeres than MSI- cancers, perhaps 
related to DNA-mismatch repair deficiency associated 
hypermutation at telomeric repeats [13, 21]. This 
phenotype may be particularly evident for TP53 wild-type 
tumors [13]. Our data did not validate this contention, with 
MSI+ and MSI- cancers showing similar telomere length 
even when taking TP53 mutation status into account. 
Similar results were observed for CIMP-H status, a marker 
closely related to the presence of MSI.
Loss of p53 pathway function in primary human 
cells allows cells to bypass the senescence checkpoint 
associated with telomere attrition [13, 22]. We found no 
association between TP53 mutation status and telomere 
length. p53 is a known negative regulator of hTERT 
promoter, and mutated p53 may result in hTERT activation 
counteracting telomere attrition [43]. Some data suggest 
a role of EGFR signaling in regulating the telomerase 
complex, perhaps related to response to anti-EGFR 
antibody therapy [44, 45]. We found no evidence for an 
association of KRAS or BRAF mutation with telomere 
length.
While multiple studies indicate that telomerase 
activity is associated with prognosis in stage II/III CRC 
[46], data on the relationship between telomere length 
measurements and outcome are limited. Longer cancer 
telomere length or higher cancer to non-cancer tissue 
telomere length ratios have been associated with poorer 
prognosis in three reports [11, 12, 14], but another study 
has found opposite results [9]. Variation in normal tissue 
telomere length (for PBLs) has further been suggested 
as a marker of CRC prognosis [31]. In our cohort of 
patients with stage II/III CRC we found no evidence 
of normal or cancer RTL associated with disease-free 
survival or overall survival. Our observation is consistent 
with emerging data that TERT levels and/or telomerase 
activity may be better prognostic markers than telomere 
length [46].
Strengths of our study include the large number 
of cases, long-term follow-up and the ability to adjust 
for major confounders. Our survey also has inherent 
limitations that relate to the applied methods. We used 
qPCR to measure RTL, rather than absolute telomere 
length per se, because qPCR is the only practical high-
throughput method for large-scale epidemiologic studies. 
However, the RTL qPCR method developed by Cawthon 
[32] has previously been shown to highly correlate 
with absolute telomere length measurements in tumor 
and normal samples by Southern blotting [13], and we 
confirmed a high correlation of human beta globin gene 
and total chromosome number in our tumors. RTL values 
represent an average telomere length measurement across 
all chromosomes, but it is clearly established that that it 
is the shortest telomere in a given cell that is responsible 
for initiating CIN [47]. However, the well-documented 
association between average telomere length and cancer 
risk in human and animal models indicates a tractable 
direct correlation between average and shortest telomere 
length [28-30]. Only single normal mucosa samples 
were available per patient in our study, thus whether 
nRTL measurements in tumor-adjacent mucosa were 
representative of the entire colorectum or potentially 
pertained to a field effect – as has been suggested by some 
investigators [48] - could not be examined. However our 
normal biopsies showed no evidence of mutations, CIMP 
or DNA copy number changes.
The development of telomerase inhibitors as 
experimental cancer treatment highlights the importance 
of understanding tumor telomere length variability and its 
relationship to patient characteristics, molecular features 
and outcome [49]. Our findings identify patient baseline 
clinical and genetic modifiers of normal mucosa telomere 
length, and reveal independent contributions of normal 
and tumor telomere length to disease progression. We 
further demonstrate divergent associations of cancer 
telomere length with distinct CIN profiles. Our results do 
not support a prognostic value of RTL in resected stage II/
III CRC.
MATERIALS AND METHODS
Patients
A total of 419 patients with CRC and 90 patients 
with colorectal adenomas were retrieved from biobanks 
of two centers, The Royal London Hospital in the 
United Kingdom and The Royal Melbourne Hospital 
in Australia. Patients with involved resection margins, 
hereditary CRC syndromes, ulcerative colitis or Crohn’s 
disease-associated CRC were excluded, and tumours 
were required to have a greater than 70% neoplastic 
cell content. Among patients with CRC, 71 had stage 
I, 155 stage II, 151 stage III, and 42 stage IV disease. 
195 were proximal colon (cecum to transverse colon), 
142 were distal colon (splenic flexure to rectosigmoid) 
and 82 were rectal cancers. Patient characteristics are 
summarized in Supplementary Table 2. Paired liver 
metastases were available for 11 primary cancers. Body 
mass index, smoking history, clinical, treatment and 
follow-up data were prospectively recorded. This study 
was human research ethics committee-approved, and all 
patients gave informed consent.
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DNA extraction
Fresh-frozen tumor and normal tissues were 
collected at surgery and macrodissected following 
histologic review of an H&E-stained section, with tumor 
areas comprising greater than 70% neoplastic cells 
(median=80%). Genomic DNA was extracted using the 
DNAeasy Blood & Tissue DNA Isolation Kit (QIAGEN).
Microsatellite instability analysis
The Bethesda consensus panel of microsatellite 
markers (BAT25, BAT26, D2S123, D5S346, and 
D17S250) was used to determine tumor MSI status. 
DNA was PCR-amplified for matched tumor and normal 
samples using fluorescently labeled primers and reaction 
products were analyzed on a 3130xl Genetic Analyzer 
(Applied Biosystems). MSI+ was diagnosed if instability 
was detected at 2 or more markers.
Mutation detection
DNA sequencing was performed for KRAS (codons 
12, 13 and 61), BRAF (codon 600), PIK3CA (exons 9 and 
20) and TP53 (exons 4-9) on a 3730xl DNA Analyzer 
(Applied Biosystems) using the BigDye Terminator 
v3.1 Ready Reaction Mix (Applied Biosystems; details 
available from authors). Detected mutations were 
confirmed by resequencing of tumor and matched normal 
DNA from new PCR product.
CIMP marker analysis
Tumor CIMP status was determined using 
MethyLight real-time PCR for the 5 marker panel 
developed by Weisenberger et al. (IGF2, SOCS1, RUNX3, 
CACNA1G, and NGN1) in the Australian samples [50], 
and for the 6 marker panel developed by Toyota et al. 
(MINT1, MINT2, MINT31, p16INK4a, p14ARF, MLH1) in the 
United Kingdom samples as described [51]. Tumors with 
methylation at 3 or more CIMP markers were classified 
as CIMP+.
Genotyping
Genotypes for germline variants associated with 
telomere length (Supplementary Table 1) in the population 
were retrieved from existing Illumina Human610-Quad 
BeadChip data for our carcinoma patients [30]: ACYP2, 
rs11125529 (proxy rs10165485); BCL2L1, rs6060627; 
CTC1, rs3027234 (proxy rs11651199); CXCR4, rs4452212 
(proxy rs10221893); MEN1, rs669976, rs509386, 
rs2957154, rs670358; MRE11A, rs12270338, rs13447720; 
NAF1, rs7675998 (proxy rs11100479); OBCF1, 
rs2487999, rs9419958, rs9420907; RECQL5, rs820152; 
RTEL1, rs755017 (proxy rs2281929); TERC, rs10936599, 
rs12696304 (proxy rs1997392), rs6793295; TERT, 
rs2736100; TNKS, rs11991621, rs12549064, rs10903314, 
rs6990300, rs11249943, rs17150478; ZNF208, 
rs8105767 (proxy rs7257051); ZNF676, rs412658 (proxy 
rs10419926). SNP array-based genotyping results for 
rs2736100 have previously been validated using KASPar 
competitive allele-specific PCR chemistry (KBiosciences 
Ltd, Hoddesdon UK [30]).
CIN assessment using SNP microarrays
Tumor CIN status was determined from existing 
Illumina Human610-Quad BeadChip data on matched 
tumor and normal DNA using OncoSNP as described 
previously [52]. Briefly, copy-number for individual 
autosomes was estimated by calculating the mode of 
absolute DNA copy-numbers across SNPs, and the 
total autosome number was determined for each cancer. 
The number of chromosome breaks was recorded for 
each tumor. Accuracy of total autosome copy-number 
estimates has previously been confirmed using 32 CRC 
cell lines with standard karyotype data [52]. Tumors 
with ≤3 whole-autosome changes were classified as 
CIN-, tumors with a modal autosome copy-number of 4 
were classified as near-tetraploid, and other tumors with 
>3 autosome copy-number changes were classified as 
aneuploid.
Telomere length analysis
RTL was measured using the monochrome 
multiplex quantitative polymerase chain reaction (qPCR) 
method developed by Cawthon [32]. Briefly, telomeric 
DNA (T) and a single-copy internal control (S) gene 
(the human beta globin gene) were amplified for each 
sample on a 7500 Fast Real-time PCR System (Applied 
Biosystems) on two occasions, RTL was calculated as T/S 
ratio against a standard curve. Matched tumor and normal 
samples were analyzed in the same qPCR plate together 
with references cell line samples with established short 
telomere length (TF-1: human hematopoietic progenitor 
cell line, 3.76 Kb ) and long telomere lengths(TF-1/TI2G: 
TF-1 cell line with retroviral overexpression of hTERT, 
9.92 kb) (Supplementary Figure 3) [33]. Reference 
samples were readily distinguishable with a mean RTL of 
0.73 (SD=0.13) for TF-1 and 3.06 (SD=0.37) for TF-1/
TI2G. RTL measurements across repeat assays were 
highly consistent (normal, r=0.91; tumor, r=0.96), with an 
inter-assay coefficient of variability of 7.5% and 8.4% for 
normal and tumor samples, respectively (Supplementary 
Figure 2). RTL measurements for repeat assays were 
averaged. Validity of using the human beta globin gene 
as internal control (S) gene in aneuploidy tumor samples 
was confirmed in our SNP array data, exhibiting a high 
correlation with total autosome number (r=0.86, P<0.001; 
Supplementary Figure 1).
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Statistical analysis
Statistical analyses were conducted using the 
statistical computing software R (R Development Core 
Team, 2011). Univariate analyses for differences between 
groups used Fisher exact test for categorical variables and 
Student’s t test for continuous variables. For the analyses 
for germline variants, an additive genotype model was 
used. Multivariate analyses for association between RTL 
and clinicopathological and molecular features were 
conducted using logistic regression. Outcome analyses for 
patients with resected stage II/III CRC were performed for 
5-year disease-free survival (DFS), and overall survival 
(OS). DFS was defined as time from surgery to the first 
confirmed relapse, with censoring done when a patient 
died or was alive without recurrence at last contact. 
OS was defined as time from surgery to death, with 
censoring done when a patient was alive at last contact. 
Survival curves were generated according to the method 
of Kaplan and Meier. Univariate survival distributions 
were compared using the log-rank test, and multivariate 
analyses used Cox proportional hazards models. A two-
sided P-value of <0.05 was considered significant.
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